Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin

Cancer Research

Volumn 64, Issue 22, 2004, Pages 8381-8388

  Pizzoferrato, Eva ^a,b   Liu, Ye ^a   Gambotto, Andrea ^a,b   Armstrong, Michaele J ^a   Stang, Michael T ^a   Gooding, William E ^a   Alber, Sean M ^a   Shand, Stuart H ^a   Watkins, Simon C ^a   Storkus, Walter J ^a,b   Yim, John H ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DOXORUBICIN; INTERFERON REGULATORY FACTOR 1; PROTEIN P21; PROTEIN P53; SURVIVIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR MODEL;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOXORUBICIN; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTOR-1; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHOSPHOPROTEINS;

EID: 8544231419     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2223     Document Type: Article

References (50)

1. Miyamoto M, Fujita T, Kimura Y, et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-B gene regulatory elements. Cell 1988;54:903-13.
2. Geller DA, Nguyen D, Shapiro RA, et al. Cytokine induction of interferon regulatory factor-1 in hepalocytes. Surgery 1993;114:235-42.
3. Galon J, Sudarshan C, Ito S, Finbloom D, O'Shea JJ. IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. J Immunol 1999;162:7256-62.
4. Gupta S, Xia D, Jiang M, Lee S, Pernis AB. Signaling pathways mediated by the TNF- and cytokine-receptor families target a common cis-element of the IFN regulatory factor 1 promoter. J Immunol 1998;161:5997-6004.
5. Tanaka N, Ishihara M, Taniguchi T. Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. Cancer Lett 1994;83:191-6.
6. Nozawa H, Oda E, Nakao K, et al. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 1999;13:1240-5.
7. Doherty GM, Boucher L, Sorenson K, Lowney J. Interferon regulatory factor expression in human breast cancer. Ann Surg 2001;233:623-9.
8. Bouker KB, Skaar TC, Fernandez DR, et al. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Res 2004;64:4030-9.
9. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
10. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20.
11. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-Ex3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999;59:6097-102.
12. Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 2000;19:1346-53.
13. Velculescu VE, Madden SL. Zhang L, et al. Analysis of human transcriptomes. Nat Genet 1999;23:387-8.
14. Nasu S, Yagihashi A, Izawa A, et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res 2002;22:1839-43.
15. Tanaka K, Iwamoto S. Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34.
16. Kayaselcuk F, Nursal TZ, Polat A, et al. Expression of survivin, bcl-2, P53 and bax in breast carcinoma and ductal intraepithelial neoplasia (DIN 1a). J Exp Clin Cancer Res 2004;23:105-12.
17. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001;34:207-12.
18. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542-7.
19. Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 2003;10:87-95.
20. Nieves-Neira W, Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen, multifactorial relationships with topoisomerase I, protein kinase C, bcl-2, p53, MDM2 and caspase pathways. Int J Cancer 1999;82:396-404.
21. Concin N, Zeillinger C, Tong D, et al. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat 2003;79:37-46.
22. Rolley N, Butcher S, Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene 1995;11:763-70.
23. Ryan KM, Vousden KH. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998;18:3692-8.
24. Kim PKM, Armstrong M, Liu Y, et al. IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene 2004;23:1125-35.
25. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997;71:1842-9.
26. Chang CH, Hammer J, Loh JE, Fodor WL, Flavell RA. The activation of major histocompatibility complex class I genes by interferon regulatory factor-1 (IRF-1). Immunogenetics 1992;35:378-84.
27. Reis LFL, Harada H, Wolchok JD, Taniguchi T, Vilcek J. Critical role of a common transcription factor, IRF-1, in the regulation of IFN-β and IFN-inducible genes. EMBO J 1992;11:185-93.
28. Yim JH, Ro SH. Lowney JK, et al. The role of interferon regulatory factor-1 and interferon regulatory factor-2 in IFN-γ growth inhibition of human breast carcinoma cell lines. J Interferon Cytokine Res 2003;23:501-11.
29. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
30. Girdlestone J, Isamat M, Gewert D, Milstein C. Transcriptional regulation of HLA-A and -B: differential binding members of the Rel and IRF families of transcription factors. Proc Natl Acad Sci USA 1993;90:11568-72.
31. 1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
32. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995;55:2910-9.
33. Coccia EM. Del Russo N, Stellacci E, et al. Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2. Oncogene 1999;18:2129-37.
34. Lohr K. Moritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 2003;35:32507-16.
35. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613-22.
36. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-57.
37. 1 cyclin-dependent kinases. Cell 1993;75:805-16.
38. Xiong Y, Hannon G, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature (Lond) 1993;366:701-4.
39. 2/M-phase transition. Mol Cell Biol 1998;18:546-57.
40. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998;18:629-43.
41. 1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res 1995;55:2075-80.
42. 1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J 2996;15:2748-59.
43. Biggs JR, Kudlow JE, Kraft AS. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem 1996;271:901-6.
44. WAF1/Cip1. Nature 1997;389:187-90.
45. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21/WAF1/CIP1 expression. Nat Genet 1997;15:78-82.
46. Tanaka N, Ishihara M, Lamphier MS, et al. Cooperation of the tumor suppressors IRF-1 and p53 in response to DNA damage. Nature (Lond) 1996;382:816-8.
47. Armstrong M, Stang MT, Liu Y, et al. p53 status determines IRF-1 induction of p21 and growth inhibition in HCT116 colon cancer cells. J Surg Res 2003;114:301-2.
48. Chang Q, Liu ZR, Wang DY, et al. Survivin expression induced by doxorubicin in cholangiocarcinoma. World J Gastroenterol 2004;10:415-8.
49. Moriai R, Asanuma K, Kobayashi D, et al. Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res 2001;21:595-600.
50. Notarbartolo M, Cervello M, Dusonchet L, Cusimano D, D'Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein. Fas and of the novel anti-apoptosis factors IAP (inhibitor of apoptosis proteins). Cancer Lett 2002;180:91-101.